HYPERFINE Stock Price, News & Analysis

Hyperfine, Inc. (Nasdaq: HYPR) will announce its financial results for Q4 and full-year 2021 on March 23, 2022, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET. The company developed Swoop®, the first FDA-cleared portable MRI system, aimed at enhancing patient access to diagnostic imaging. Swoop's affordability and ease of use allow rapid diagnoses in various clinical settings, offering high-quality imaging at lower magnetic field strengths.

Hyperfine, creator of the first FDA-cleared portable MRI system, Swoop, announced participation in the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 2:10 PM ET. The presentation will be accessible via a live and archived webcast on their website's Investors section. Swoop enables rapid diagnosis and treatment at point-of-care settings, producing high-quality images with lower magnetic field strength, offering significant benefits in emergency and critical care environments.

Hyperfine, Inc. (Nasdaq:HYPR) announced the deployment of its Swoop portable MRI system at Queen's University and Kingston Health Sciences Centre in Northern Ontario. This move aims to enhance healthcare access for six remote communities, alleviating the need for lengthy medical transfers due to conventional MRI unavailability. The initiative will also support a study on the utility of the portable MRI in remote settings. Hyperfine's recent Health Canada medical device license and commercial launch further validates its innovative approach to imaging technology.

Hyperfine Inc. has appointed Dr. Chip Truwit as the new senior medical director, enhancing its leadership for the growth of its portable MRI technology. Dr. Truwit, a seasoned expert in neuroradiology, previously led diagnostic imaging at Philips Healthcare. His extensive experience, including over 130 published articles and numerous patents, will support Hyperfine’s mission to broaden access to critical MRI imaging. This strategic move aims to improve hospital workflows and enhance care for underserved populations, especially children.

Hyperfine announces the deployment of its FDA-cleared portable MRI, Swoop, at M Health Fairview University of Minnesota Medical Center, marking a significant advancement in neurosurgery technology. This system allows for quick patient scans directly at the bedside, reducing wait times and transportation challenges. Swoop enhances patient safety and diagnostics with AI-driven capabilities, producing high-quality images in minutes. It has previously been deployed at various prestigious medical centers, further establishing its role in improving patient care.

Hyperfine (Nasdaq: HYPR) announced preliminary unaudited revenue figures for Q4 and the full year 2021, predicting revenues of approximately $0.362 to $0.437 million for Q4 and $1.42 to $1.50 million for the entire year. The company also secured $0.81 million in grant funding for Q4 and $1.45 million for the year. Despite challenges, Hyperfine installed over 50 Swoop devices in 2021, emphasizing growth potential in portable MRI technology.

Hyperfine (Nasdaq: HYPR) announces its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. ET. The company, known for its FDA-cleared portable MRI system Swoop®, strives to enhance patient access to diagnostic imaging. Interested parties can view the live and archived presentation on the company's investor website. The Swoop system enables rapid scans directly at the patient's bedside, providing critical imaging at a lower cost, making it a valuable tool for emergency departments, operating rooms, and intensive care units.

Hyperfine Inc. has completed its business combination with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ), securing approximately $160 million in gross cash proceeds. This funding aims to accelerate the growth initiatives for its Swoop® portable MRI system, designed to enhance patient access to MRI technology. Trading under the ticker HYPR will commence on December 23, 2021. Hyperfine focuses on transforming medical imaging with Swoop, aiming to expand both domestically and internationally while addressing healthcare disparities.

Hyperfine and Liminal announced a definitive agreement for a business combination with HealthCor Catalio Acquisition Corp (Nasdaq: HCAQ). This merger creates a combined company valued at approximately $580 million, with expected cash resources around $375 million. The transaction aims to enhance accessibility and affordability in MRI imaging through Hyperfine's FDA-cleared Swoop™ device and Liminal's brain monitoring innovations. The merger is anticipated to close in Q4 2021, pending shareholder approvals and customary conditions.